My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,076.98 +5.34 (+0.50%)

Official Closing Price Updated: 1:10 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

2 Monster Stocks to Hold for the Next 5 Years ↗

September 11, 2025

These companies each are leaders in today's highest-growth industries.

Via The Motley Fool

Topics Artificial Intelligence

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets ↗

September 10, 2025

ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices.

Via Benzinga

The Smartest Vanguard ETF to Buy With $1,000 Right Now ↗

September 10, 2025

A fund like the Vanguard Dividend Appreciation ETF can help hedge against a potential market pullback.

Via The Motley Fool

Topics ETFs

Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ ↗

September 09, 2025

Via Stocktwits

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' ↗

September 10, 2025

Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant...

Via Benzinga

Defiance Has A New ETF For High-Stakes Pharma Traders ↗

September 09, 2025

Defiance's LLYZ ETF offers 2X inverse daily exposure to Eli Lilly, giving traders a high-risk, short-term way to bet on stock pullbacks without shorting.

Via Benzinga

Topics ETFs

Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data ↗

September 09, 2025

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research.

Via Benzinga

Topics Artificial Intelligence

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies ↗

September 09, 2025

The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated.

Via Stocktwits

Topics Artificial Intelligence

2 Growth Stocks with Explosive Upside and 1 We Brush Off

September 09, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Topics Credit Cards

1 Reason Every Investor Should Know About Novo Nordisk (NVO) ↗

September 08, 2025

The company could be on the verge of turning the tide in the battle over weight loss drugs.

Via The Motley Fool

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients ↗

September 08, 2025

Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 trial, with positive trends in overall survival.

Via Benzinga

2024 R&D Spending and Intensity Benchmarks

September 08, 2025

Via PRLog

Topics Supply Chain

Ozempic Is The New Botox And Big Pharma Is Printing Billions ↗

September 08, 2025

Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.

Via Benzinga

Looking At Eli Lilly's Recent Unusual Options Activity ↗

September 08, 2025

Via Benzinga

Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks

September 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List ↗

September 07, 2025

FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments.

Via Benzinga

Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. ↗

September 07, 2025

The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.

Via The Motley Fool

The Best Growth ETF to Invest $2,000 in Right Now ↗

September 07, 2025

This ETF has shown long-term market-beating ability.

Via The Motley Fool

Topics ETFs

3 Stocks to Buy and Hold Forever ↗

September 06, 2025

These stocks are built for the long run.

Via The Motley Fool

Topics Intellectual Property

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗

September 05, 2025

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

Via Benzinga

Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? ↗

September 05, 2025

The company's innovative engine continues to function well.

Via The Motley Fool

Topics World Trade

2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts ↗

September 05, 2025

Consensus price targets set by experts who follow these businesses are way above their recent prices.

Via The Motley Fool

Topics Stocks

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Viking aims to enter the billion-dollar weight loss drug market.

Via The Motley Fool

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer ↗

September 04, 2025

Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results.

Via Benzinga

ETF Traders Are Quietly Positioning For Market Turbulence: Direxion ↗

September 04, 2025

Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves.

Via Benzinga

Topics ETFs

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Both companies have made significant progress in recent years.

Via The Motley Fool

The 6 Best Stocks to Buy Right Now in September (2025)! ↗

September 04, 2025

There is something for everyone in this list of excellent stocks to buy.

Via The Motley Fool

Where Will Eli Lilly Be in 3 Years? ↗

September 04, 2025

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.